Ultimate Assessment Program 2027/28/29 || 1:1 Mentorship Batch Admissions Open

Why in the News

The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) sells medicines at about 80% below market prices, yet its outlets number only about 1.7% of the country’s reported chemists. Low awareness, doctors’ reluctance and doubts over quality and stock have held it back. Medicines dominate household health spending, so the case is for a national survey and dedicated funds.

What is Jan Aushadhi, and how far has it reached?

  1. What it is: A government network of Jan Aushadhi Kendras selling generic medicines (same active ingredient as branded drugs, sold under the chemical name). It works like a fair-price shop for medicines.
  2. Who runs it: Launched in 2008 and revamped in 2015, it is run through the Pharmaceuticals and Medical Devices Bureau of India (PMBI) under the Department of Pharmaceuticals.
  3. What it sells: 2,110 medicines and 315 surgical items.
  4. How far it has grown: The number of Kendras reached 20,547 by July 2026.
  5. The takeaway: The scheme cuts medicine bills sharply, so its limited reach leaves avoidable costs on households.

Why has the scheme not caught on?

  1. Thin network: India has a reported 12 lakh chemists, an industry figure, since no official count exists. Saving rent can place Kendras in quieter areas.
  2. Low awareness: Among outpatients studied in Port Blair, only a third had heard of the scheme, and over half did not know what outlets sell.
  3. ‘Poor only’ image: Some see the Kendras as shops for the poor.
  4. Prescriber resistance: The National Medical Commission ordered doctors to prescribe by generic name. Doctors’ bodies objected, citing autonomy, accountability and quality, and the order was put on hold.

Can quality checks and full shelves build trust?

  1. Quality safeguards: Suppliers must hold WHO-GMP certification (the World Health Organization’s Good Manufacturing Practice standard), and every batch must be tested.
  2. Recall record: A 2020 report counted recalled batches but not how many were tested, so the failure rate cannot be worked out.
  3. Substandard rate: The reported share of substandard (quality-failing) medicines is 0.34%, against 3.70% in the open market. No period or testing method is given.
  4. Stock-outs: An empty shelf loses buyers, and fewer buyers mean the shop stocks fewer medicines.
  5. Shops for everyone: Use by all income groups raises demand and manufacturer volumes. India supplies one-fifth of the world’s generics, so manufacturing is not the constraint.

Why does it matter for household health spending?

  1. Medicines dominate costs: Medicines are roughly 60 to 70% of household out-of-pocket expenditure on health, paid by families themselves.
  2. Insurance gap: The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana mainly pays for hospital admission. Medicines bought without admission stay largely uncovered.
  3. Public spending shortfall: Government health expenditure was 1.43% of gross domestic product (GDP) in 2023-24, below the National Health Policy target.
  4. Dedicated allocation: As health spending rises, a dedicated share should fund expanding and promoting Jan Aushadhi.

Challenges

  1. No evidence on users: Data cover outlets, footfall and sales, but not why people use or avoid the Kendras.
  2. Unverified quality claims: Without testing details, the low substandard rate cannot persuade doctors.
  3. Weak stock management: Reordering is not tied to live demand, so shortages recur.

Way Forward

  1. National survey: The Department of Pharmaceuticals and the Health Ministry should commission a users’ survey with an independent academic partner.
  2. Published batch tests: Release the Indian Pharmacopoeia Commission‘s random tests with period, method and laboratories.
  3. Online stock tracking: Reorder automatically so stores seldom run out.
  4. Generic prescribing, with proof: Restore the mandate once quality is proven, showing bioequivalence (acting in the body like the branded drug) on labels.
  5. Promotion for all: Market Kendras through social media and the Jan Aushadhi Sugam app (store locator and price list).

Conclusion

Jan Aushadhi has shown that generics can be sold far below market prices nationwide, but public demand has not kept pace. Unresolved is whether evidence on users, verifiable quality and dedicated funding arrive together, since any one alone leaves families overpaying.

Key numbers

  1. Outlets: 17,990 at the end of December 2025; target of 25,000 Kendras by March 2027.
  2. Daily footfall: 10 to 12 lakh visitors a day (government estimate).
  3. Sales and savings: Rs 2,252 crore at maximum retail price in 2025-26; savings of about Rs 9,000 crore that year, Rs 45,000 crore over 12 years (government estimates).
  4. Recall count: 106 batches recalled over four years (2020 report).
  5. Generic requests: only 6% of Port Blair outpatients had ever asked a doctor for generics.
  6. Health spending target: 2.5% of GDP by 2025 (National Health Policy), unmet.

Matching Previous Year Question

“No direct PYQ traced in the provided files. Thematic PYQ: [2024] With reference to the ‘Pradhan Mantri Surakshit Matritva Abhiyan’, consider the following statements: 1. This scheme guarantees a minimum package of antenatal care services to women in their second and third trimesters of pregnancy and six months post-delivery health care service in any government health facility. 2. Under this scheme, private sector health care providers of certain specialities can volunteer to provide services at nearby government health facilities. Which of the statements given above is/are correct? (a) 1 only (b) 2 only (c) Both 1 and 2 (d) Neither 1 nor 2 ANSWER: (b)”

Click here to Download X-Factor Notes for FREE. Cover the entire Microthemes with PYQs.

Download free X-Factor Notes
Revised and updated X-Factor Notes for UPSC Mains 2026: nine subject booklets